Federated Hermes’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Federated Hermes’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,083	Closed	-$137K	–	2276
2022 Q2	$137K	Hold	1,083	–	–	﹤0.01%	1584
2022 Q1	$137K	Sell	1,083 -916,519	-100%	-$103M	﹤0.01%	1629
2021 Q4	$120M	Buy	917,602 +311	+0%	+$40.2K	0.22%	119
2021 Q3	$112M	Sell	917,291 -14,693	-2%	-$1.7M	0.21%	122
2021 Q2	$106M	Sell	931,984 -58,322	-6%	-$6.82M	0.2%	140
2021 Q1	$119M	Buy	990,306 +464,313	+88%	+$52.6M	0.23%	118
2020 Q4	$53.4M	Buy	525,993 +185,872	+55%	+$17.2M	0.11%	234
2020 Q3	$26.3M	Sell	340,121 -11,825	-3%	-$1.01M	0.06%	352
2020 Q2	$39.2M	Buy	351,946 +55,535	+19%	+$4.83M	0.1%	245
2020 Q1	$21.3M	Buy	296,411 +296,409	+14,820,450%	+$25.3M	0.06%	321
2019 Q4	$1K	Buy	+2	New	+$88	﹤0.01%	2162

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Federated Hermes's KRTX Position: Q3 2022 in Review

Federated Hermes sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2022, closing a stake of 1,083 shares — an estimated $137K sold.

Federated Hermes first reported a position in KRTX in Q4 2019 and held it in 11 quarters. The position peaked at $120M in Q4 2021. 257 funds tracked by Wall St. Rank hold KRTX as of Q3 2022.

Federated Hermes reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Federated Hermes sold 1,083 Karuna Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $137K.
Federated Hermes first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
Federated Hermes's Karuna Therapeutics, Inc. Common Stock position peaked at $120M in Q4 2021.
257 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Federated Hermes's 13F filing for Q3 2022, filed 14 Nov 2022.